Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma.
作者信息
Chang Lih-Chyun, Chen Kuan-Yu, Shih Jin-Yuan, Yu Chong-Jen, Hsieh Min-Shu
机构信息
Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
出版信息
J Thorac Oncol. 2017 Jul;12(7):e94-e95. doi: 10.1016/j.jtho.2017.03.004.
PMID:28629547
Abstract
摘要
相似文献
1
Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma.一例肺腺癌患者中BRAF突变与EGFR外显子20插入共存
J Thorac Oncol. 2017 Jul;12(7):e94-e95. doi: 10.1016/j.jtho.2017.03.004.
2
Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.肺腺癌中表皮生长因子受体（EGFR）、KRAS 和 BRAF 突变：来自印度的一项研究。
Curr Probl Cancer. 2019 Oct;43(5):391-401. doi: 10.1016/j.currproblcancer.2018.12.003. Epub 2018 Dec 17.
3
Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.检测脑脊液转移细胞中的 EGFR、KRAS 和 BRAF 突变。
Clin Chem Lab Med. 2018 Apr 25;56(5):851-856. doi: 10.1515/cclm-2017-0527.
4
A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.一例表皮生长因子受体（EGFR）第19外显子新型倒位突变导致肺腺癌对EGFR酪氨酸激酶抑制剂原发性耐药的病例
J Thorac Oncol. 2018 Jun;13(6):e97-e101. doi: 10.1016/j.jtho.2017.12.014. Epub 2018 Feb 28.
5
An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.在对达拉非尼加曲美替尼耐药的BRAF V600E突变型肺腺癌中获得性NRAS Q61K突变
J Thorac Oncol. 2018 Aug;13(8):e131-e133. doi: 10.1016/j.jtho.2018.03.026. Epub 2018 Apr 6.
6
EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.EGFR外显子18 DelE709_T710insD作为晚期EGFR外显子18 E709H肺腺癌对阿法替尼获得性耐药的机制
J Thorac Oncol. 2018 Jun;13(6):e93-e95. doi: 10.1016/j.jtho.2018.01.006.
7
Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.低剂量阿法替尼联合西妥昔单抗对一名具有新型表皮生长因子受体（EGFR）外显子20插入突变的腺癌患者的持久疗效
J Thorac Oncol. 2019 Oct;14(10):e220-e221. doi: 10.1016/j.jtho.2019.05.023.
8
Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.多灶性肺腺癌患者中表皮生长因子受体突变与EML4-ALK融合并存
J Thorac Oncol. 2018 Mar;13(3):e45-e48. doi: 10.1016/j.jtho.2017.11.130.
9
Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.在对阿法替尼和克唑替尼联合治疗敏感的肺腺癌中鉴定出一种与EGFR突变共存的新型MET外显子14跳跃变体
J Thorac Oncol. 2019 Apr;14(4):e70-e72. doi: 10.1016/j.jtho.2018.11.026.
10
A Case of Adenocarcinoma of the Lung With EGFR T790 Mutation Presenting With Chylous Ascites.1例伴有EGFR T790M突变的肺腺癌合并乳糜性腹水病例。
J Thorac Oncol. 2018 Aug;13(8):1227-1228. doi: 10.1016/j.jtho.2018.03.029. Epub 2018 Apr 6.
Zotero 插件